0001442999 false 2024 Q2 --03-31 0001442999 2023-04-01 2023-09-30 0001442999 2023-11-11 0001442999 2023-09-30 0001442999 2023-03-31 0001442999 2023-07-01 2023-09-30 0001442999 2022-07-01 2022-09-30 0001442999 2022-04-01 2022-09-30 0001442999 us-gaap:CommonStockMember 2022-03-31 0001442999 us-gaap:TreasuryStockCommonMember 2022-03-31 0001442999 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001442999 ABTI:StockSubscriptionMember 2022-03-31 0001442999 us-gaap:ComprehensiveIncomeMember 2022-03-31 0001442999 us-gaap:RetainedEarningsMember 2022-03-31 0001442999 2022-03-31 0001442999 us-gaap:CommonStockMember 2023-03-31 0001442999 us-gaap:TreasuryStockCommonMember 2023-03-31 0001442999 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001442999 ABTI:StockSubscriptionMember 2023-03-31 0001442999 us-gaap:ComprehensiveIncomeMember 2023-03-31 0001442999 us-gaap:RetainedEarningsMember 2023-03-31 0001442999 us-gaap:CommonStockMember 2022-04-01 2022-09-30 0001442999 us-gaap:TreasuryStockCommonMember 2022-04-01 2022-09-30 0001442999 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-09-30 0001442999 ABTI:StockSubscriptionMember 2022-04-01 2022-09-30 0001442999 us-gaap:ComprehensiveIncomeMember 2022-04-01 2022-09-30 0001442999 us-gaap:RetainedEarningsMember 2022-04-01 2022-09-30 0001442999 us-gaap:CommonStockMember 2023-04-01 2023-09-30 0001442999 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-09-30 0001442999 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-09-30 0001442999 ABTI:StockSubscriptionMember 2023-04-01 2023-09-30 0001442999 us-gaap:ComprehensiveIncomeMember 2023-04-01 2023-09-30 0001442999 us-gaap:RetainedEarningsMember 2023-04-01 2023-09-30 0001442999 us-gaap:CommonStockMember 2022-09-30 0001442999 us-gaap:TreasuryStockCommonMember 2022-09-30 0001442999 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001442999 ABTI:StockSubscriptionMember 2022-09-30 0001442999 us-gaap:ComprehensiveIncomeMember 2022-09-30 0001442999 us-gaap:RetainedEarningsMember 2022-09-30 0001442999 2022-09-30 0001442999 us-gaap:CommonStockMember 2023-09-30 0001442999 us-gaap:TreasuryStockCommonMember 2023-09-30 0001442999 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001442999 ABTI:StockSubscriptionMember 2023-09-30 0001442999 us-gaap:ComprehensiveIncomeMember 2023-09-30 0001442999 us-gaap:RetainedEarningsMember 2023-09-30 0001442999 ABTI:IssuanceOneMember 2010-04-02 2010-05-03 0001442999 ABTI:IssuanceTwoMember 2021-01-01 2021-01-29 0001442999 2021-05-28 0001442999 ABTI:PatentPTXMember 2023-07-05 2023-07-05 0001442999 ABTI:AuditFeesMember 2023-09-30 0001442999 ABTI:AuditFeesMember 2023-03-31 0001442999 ABTI:AccountingMember 2023-09-30 0001442999 ABTI:AccountingMember 2023-03-31 0001442999 ABTI:ResearchAndDevelopmentMember 2023-09-30 0001442999 ABTI:ResearchAndDevelopmentMember 2023-03-31 0001442999 us-gaap:GeneralAndAdministrativeExpenseMember 2023-09-30 0001442999 us-gaap:GeneralAndAdministrativeExpenseMember 2023-03-31 0001442999 ABTI:LegalAndTransferAgentMember 2023-09-30 0001442999 ABTI:LegalAndTransferAgentMember 2023-03-31 0001442999 ABTI:ConsultancyAgreementMember 2021-09-01 2021-09-30 0001442999 ABTI:SubscriptionMember 2022-05-02 2022-05-02 0001442999 ABTI:InvestorIssuanceThreeMember 2022-05-02 2022-05-02 0001442999 ABTI:DirectorIssuanceMember 2022-05-04 2022-05-04 0001442999 ABTI:DirectorIssuanceMember 2022-05-04 0001442999 ABTI:LoanAgreementIssuanceMember 2022-08-01 2022-08-01 0001442999 ABTI:WarrantSharesMember 2021-08-11 2021-08-11 0001442999 ABTI:WarrantSharesMember 2021-08-11 0001442999 ABTI:WarrantSharesMember 2023-03-31 0001442999 ABTI:WarrantSharesMember 2021-08-01 2021-08-11 0001442999 ABTI:InvestorIssuanceTwoMember 2022-04-05 2022-04-05 0001442999 ABTI:InvestorIssuanceTwoMember 2022-04-05 0001442999 ABTI:ConsultancyAgreementMember 2022-04-29 2022-04-29 0001442999 ABTI:ConsultancyAgreementMember 2022-04-29 0001442999 ABTI:WarrantSharesMember 2023-09-30 0001442999 2021-10-29 2021-10-29 0001442999 ABTI:EMC2CapitalMember 2021-10-29 2021-10-29 0001442999 ABTI:APANov9Member 2021-11-09 2021-11-09 0001442999 ABTI:APANov9Member 2021-11-09 0001442999 2021-12-31 0001442999 2023-09-08 0001442999 ABTI:ConsultingAgreementMember 2022-03-03 2022-03-03 0001442999 2023-06-06 2023-06-06 0001442999 ABTI:EMC2CapitalLLCMember 2023-06-13 2023-06-13 0001442999 ABTI:AlisonBurgessMember 2023-06-13 2023-06-13 0001442999 ABTI:AlinovaBiosciencesMember 2023-06-13 2023-06-13 0001442999 ABTI:LongEightLimitedMember 2023-06-13 2023-06-13 0001442999 ABTI:WarrenLawGroupMember 2023-06-13 2023-06-13 0001442999 ABTI:DirectorsMember 2023-06-14 2023-06-14 0001442999 ABTI:C2WellnessAgreementReturnAssetsMember 2023-09-08 2023-09-08 0001442999 2022-08-01 0001442999 2022-07-18 0001442999 2022-08-01 2023-12-23 0001442999 ABTI:ShareholderAdvancesMember 2023-04-01 2023-09-30 0001442999 2009-10-16 2023-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:GBP

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

☒	Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
	For the quarterly period ended September 30, 2023
	For the quarterly period ended December 31, 2023
☐	Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934
	For the transition period from __________ to __________
	Commission File Number: 333-156091

Alterola Biotech, Inc.

(Exact name of Registrant as specified in its charter)

Nevada	82-1317032
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

47 Hamilton Square Birkenhead Merseyside

CH41 5AR United Kingdom

(Address of principal executive offices)

+44 151 601 9477

(Registrant’s telephone number)

_______________________________________________________________

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days

[X] Yes [ ] No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). [X] Yes [ ] No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.

☐ Large accelerated Filer	☐ Accelerated Filer
☒ Non-accelerated Filer	☒ Smaller reporting company
	☐ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

[ ] Yes [X] No

State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 1,~~365~~382,~~531~~662,~~951~~952 shares as of ~~November~~February 1118, 2023.

Table of Contents

	TABLE OF CONTENTS	Page
PART I – FINANCIAL INFORMATION
Item 1:	Financial Statements	3
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4
Item 3:	Quantitative and Qualitative Disclosures About Market Risk	7
Item 4:	Controls and Procedures	7
PART II – OTHER INFORMATION
Item 1:	Legal Proceedings	8
Item 1A:	Risk Factors	8
Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds	8
Item 3:	Defaults Upon Senior Securities	8
Item 4:	Mine Safety Disclosure	8
Item 5:	Other Information	8
Item 6:	Exhibits	8

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

Our consolidated financial statements included in this Form 10-Q are as follows:

F-1 Consolidated Balance Sheets as of ~~September~~December 3031, 2023 (unaudited) and March 31, 2023;

F-2	Consolidated Statements of Operations for the three and ~~six~~nine months ended ~~September~~December 3031, 2023 and 2022 (unaudited);
F-3	Consolidated Statement of Stockholders’ Deficit for the ~~six~~nine months ended to ~~September~~December 3031, 2023 and 2022 (unaudited);

F-4 Consolidated Statements of Cash Flow for the ~~six~~nine months ended ~~September~~December 3031, 2023 and 2022 (unaudited);

F-5	Notes to Consolidated Financial Statements.

These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the Securities Exchange Commission (“SEC”) instructions to Form 10-Q. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the interim period ended ~~September~~December 3031, 2023 are not necessarily indicative of the results that can be expected for the full year.

Table of Contents

ALTEROLA BIOTECH, INC.

UNAUDITED CONSOLIDATED BALANCE SHEETS

AS OF ~~SEPTEMBER~~DECEMBER 3031, 2023 AND MARCH 31, 2023

	September 30, 2023			March 31, 2023
	December 31, 2023			March 31, 2023
ASSETS					(audited)
				(audited)
ASSETS
Current Assets
Bank	$	92,~~102~~574		$	8,890
VAT receivable		—			37,~~593~~953
Deferred tax asset		~~187,131~~—			189,355
Inventories		~~975~~1,015			986
TOTAL CURRENT ASSETS		197,208			237,184
Total Current Assets		3,589			237,184
Intangible assets		~~300,000~~—			12,139,779
TOTAL ASSETS	$	~~497~~3,~~208~~589		$	12,376,963
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities
Accounts payable	$	~~722~~803,~~124~~841		$	611,805
Accrued expenses		~~246~~310,~~370~~522			254,864
Loan payable, related party		1244,~~550,737~~061			1,260,434
Total Current Liabilities		21,~~519~~358,~~231~~424			2,127,103
Convertible Note Payable		—			154,313
Total Liabilities		21,~~519~~358,~~231~~424			2,281,416
Stockholders’ Equity (Deficit)
Preferred Stock, $.001 par value, 10,000,000 shares authorized, -0- shares issued and outstanding		—			—
Common Stock, $.001 par value, 2,000,000,000 shares authorized, 778,031,955 and 807,047,948 shares issued and outstanding, respectively		778,032			807,048
Common Stock, $.001 par value, 2,000,000,000 shares authorized, 1,382,662,952 and 807,047,948 shares issued and outstanding, respectively		1,382,663			807,048
Treasury stock, 29,015,993 and 0 shares held, respectively		29,016			—
Additional paid-in capital		79,~~581~~663,~~442~~971			18,927,919
Accumulated deficit		(1012,~~431~~441,~~134~~456	)		(9,576,247	)
Foreign currency translation adjustment		2010,~~621~~971			(63,173	)
Total Stockholders’ Equity (Deficit)		(21,~~022~~354,~~023~~835	)		10,095,547
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY / (DEFICIT)	$	497,208		$	12,376,963
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	3,589		$	12,376,963

See accompanying notes to ~~the unaudited consolidated~~ financial statements.

F-1

Table of Contents

ALTEROLA BIOTECH, INC.

UNAUDITED CONSOLIDATED STATEMENT OF OPERATIONS

FOR THE THREE AND ~~SIX~~NINE MONTHS ENDED ~~SEPTEMBER~~DECEMBER 3031, 2023 AND 2022

	Three months ended September 30, 2023			Three months ended September 30, 2022			Six months ended September 30, 2023			Six months ended September 30, 2022
	Three months ended December 31, 2023			Three months ended December 31, 2022			Nine months ended December 31, 2023			Nine months ended December 31, 2022
REVENUES	$	—		$	—		$	—		$	—
OPERATING EXPENSES
Accounting and audit fees		2327,~~162~~882			3219,~~898~~001			7299,~~100~~982			6786,~~815~~816
Professional fees		1273,~~895~~659			~~111~~249,~~614~~183			7280,~~185~~844			~~114~~363,~~010~~193
Research and development		—2,880			~~22,614~~—			2,880			41,086
Legal fees		—60,939			5166,~~418~~699			1273,~~899~~838			8174,~~029~~728
Directors fees and expenses		2531,~~000~~575			2127,~~852~~931			~~196~~227,~~000~~575			~~518~~546,~~640~~571
Consulting fees		15661,~~937~~421			~~155~~198,~~674~~335			~~333~~995,~~678~~099			~~283~~481,~~094~~429
Salaries and wages		3326,~~519~~857			96(92,~~448~~638	)		6996,~~458~~315			~~193~~101,~~876~~238
General and administrative expenses		23,~~644~~734			24(27,~~163~~890	)		2549,~~404~~138			5628,~~821~~931
TOTAL OPERATING EXPENSES	$	~~123~~1,~~155~~108,947		$	~~470~~540,~~682~~621		$	~~716~~1,~~724~~825,671		$	1,~~283~~823,~~371~~992
LOSS FROM OPERATIONS		(~~123~~1,~~155~~108,947	)		(~~470~~540,~~682~~621	)		(~~716~~1,~~724~~825,671	)		(1,~~283~~823,~~371~~992	)
OTHER INCOME (EXPENSE)
Interest expense		—			(38	)		—			(38	)
Income tax expense for valuation allowance on deferred tax asset		(194,800	)		—			(194,800	)		—
Gain (loss) on conversion of note		—			—			(138,163	)		—
Loss on impairment of intangible assets		(300,000	)		—			(300,000	)		—
TOTAL OTHER INCOME (EXPENSE)		(123,155	)		(38	)		(138,163	)		(38	)
Gain (loss) on conversion of note		(406,575	)		—			(544,738	)		—
PROVISION FOR INCOME TAXES		—			95,469			—			95,469
TOTAL OTHER INCOME (EXPENSE)		(901,375	)		—			(1,039,538	)		—
NET LOSS		(123,155	)		(375,252	)		(854,887	)		(1,187,941	)
PROVISION FOR INCOME TAXES		—			(5,832	)		—			101,301
NET LOSS		(2,010,322	)		(534,789	)		(2,865,209	)		(1,722,691	)
Foreign exchange translation gain (loss)		(9,650)			25,730			74,144			43,152
Comprehensive loss		(2,019,972)			(509,059)			(2,791,065)			(1,679,539)
NET LOSS PER SHARE: BASIC AND DILUTED	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED		~~800~~1,~~109~~265,~~341~~220,104			807,047,948			~~801~~948,~~824~~110,~~998~~596			806,~~332~~766,~~740~~837

See accompanying notes to ~~the unaudited consolidated~~ financial statements.

F-2

Table of Contents

ALTEROLA BIOTECH, INC.

UNAUDITED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIT)

FOR THE ~~SIX~~PERIOD ~~MONTHS~~FROM ~~PERIOD~~MARCH ~~ENDED~~31, ~~SEPTEMBER~~2022 30TO DECEMBER 31, 2023

	Common stock						Treasury Shares stock
	Shares			Amount			Shares			Amount			Additional paid in capital			Stock ~~Subscriptions~~Subscription			Accumulated other comprehensive income ( loss)			Accumulated Deficit			~~Total~~Stockholders’ Equity (deficit)
Balance, March 31, 2022		802,633,333		$	802,633			—			—			17,942,833		$	136,721		$	14,599		$	(7,833,790	)	$	11,062,996
Change in foreign currency		—			—			—			—			—			—			1743,~~423~~152			—			1743,~~423~~152
Shares issued for cash		280,000			280			—			—			—136,721			—(136,721	)		—			—			280
Shares issued for cash		384,615			385			—			—			49,615			—			—			—			50,000
Shares issued for subscription of cash		—			—			—			—			136,721			(136,721	)		—			—			—
Shares issued for services		1,500,000			1,500			—			—			319,500			—			—			—			321,000
Shares issued for services		2,250,000			2,250			—			—			479,250			—			—			—			481,500
Net loss for the period ended September 30, 2022		—			—			—			—			—			—			—			(1,187,941	)		(1,187,941	)
Net loss for the period ended December 31, 2022		—			—			—			—			—			—			—			(1,722,691	)		(1,722,691	)
Balance, September 30, 2022		807,047,948		$	807,048			—			—			18,927,919			—		$	32,021		$	(9,021,731	)	$	10,745,258
Balance, December 31, 2022		807,047,948		$	807,048			—			—			18,927,919			—		$	57,751		$	(9,556,481	)	$	10,236,237
Balance, March 31, 2023		807,047,948		$	807,048			—			—			18,927,919		$	—		$	(63,173	)	$	(9,576,247	)	$	10,095,547
Change in foreign currency		—			—			—			—			—			—			83,794			—			83,794
Foreign currency translation		—			—			—			—			—			—			74,144			—			74,144
Shares reclaimed into treasury shares		(44,064,000	)		(44,064	)		44,064,000			44,064			—			—			—			—			—
Shares issued for warrants		13,500,000			13,500			(13,500,000	)		(13,500	)		—			—			—			—			—
Shares issued for acquisition of Alinova Resources		5,000,000			5,000			(5,000,000	)		(5,000	)		~~161~~295,~~863~~000			—			—			—			~~161~~295,~~863~~000
Shares issued for services		16,088,000			16,088			(16,088,000	)		(16,088	)		305,672			—			—			—			305,672
Shares issued for services- directors		9,000,000			9,000			(9,000,000	)		(9,000	)		171,000			—			—			—			171,000
Shares issued for settlement of debt		476,000			476			(476,000	)		(476	)		14157,~~988~~339			—			—			—			14157,~~988~~339
Shares reclaimed from asset acquisition cancellation		(24,000,000	)		(24,000	)		24,000,000			24,000			(12,000,000	)		—			—			—			(12,000,000	)
Shares reclaimed from asset sale		(24,000,000	)		(24,000	)		24,000,000			24,000			(12,000,000	)		—			—			—			(12,000,000	)
Additional shares reclaimed from asset acquisition cancellation		(5,015,996	)		(5,016	)		5,015,993			5,016			—			—			—			—			—
Additional shares reclaimed from asset sale		(5,015,993	)		(5,016	)		5,015,993			5,016			—			—			—			—			—
Net loss for the period ended September 30, 2023		—			—			—			—			—			—			—			(854,887	)		(854,887	)
Shares issued for conversion of debt		587,499,996			587,500			—			—			1,762,500			—			—			—			2,350,000
Balance, September 30, 2023		778,031,955		$	778,032			29,015,993		$	29,016			7,581,442		$	—		$	20,621		$	(10,431,134	)	$	(2,022,023	)
Shares issued for outside services		8,360,306			8,360			—			—			21,737			—			—			—			30,097
Shares issued for services – internal		8,770,695			8,771			—			—			22,804			—			—			—			31,575
Net loss for the period ended December 31, 2023		—			—			—			—			—			—			—			(2,865,209	)		(2,865,209	)
Balance, December 31, 2023		1,382,662,952		$	1,382,663			29,015,996			29,016			9,663,971			—		$	10,971		$	(12,441,456	)	$	(1,354,835	)

See accompanying notes to ~~the unaudited consolidated~~ financial statements.

F-3

Table of Contents

ALTEROLA BIOTECH, INC.

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE ~~SIX~~NINE MONTHS ENDED ~~SEPTEMBER~~DECEMBER 3031, 2023 ~~AND 2022~~

	Six Months Ended September 30, 2023			Six Months Ended September 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss for the period	$	(854,887	)	$	(1,187,941	)
Adjustments to reconcile net loss to net cash flows used in operating activities
Non cash currency adjustments
Stock for services		321,760			802,500
Stock to directors		180,000			—
Shares issued for warrants		13,500			—
Treasury shares received		—			—
Stock subscriptions delivered		—			136,721
Changes in assets and liabilities:					—
Funds in attorney trust		—			12,409
Inventory		—			—
VAT receivable		37,953			14,882
Deferred tax asset		2,224			(131,917	)
Accounts payable		110,319			24,533
Accrued liabilities		(8,494	)		(34,400	)
Net Cash Used by Operating Activities		(197,625	)		(363,213	)
CASH FLOWS FROM INVESTING ACTIVITIES
Acquisition of intangible assets		35,000			—
Net Cash Used by Investing Activities		35,000			—
CASH FLOWS FROM FINANCING ACTIVITIES
Purchase of common shares for cash		(44,064	)		50,280
Treasury shares received		(170,709	)		—
Loan from related parties		290,303			246,667
Net Cash Provided by Financing Activities		75,530			296,947
Net change in cash		(87,095	)		(66,266	)
Foreign currency change		87,307			17,579
Cash and cash equivalents, beginning of period		8,890			63,816
Cash and cash equivalents, end of period	$	9,102		$	15,130
SUPPLEMENTAL CASH FLOW INFORMATION
Interest paid	$	—		$	—
Income taxes paid	$	—		$	—
NON-CASH INVESTING AND FINANCING INFORMATION
Shares issued for Services	$	321,760		$	802,500
Shares issued for Stock subscription	$	—		$	136,721
Shares issued for asset acquisition	$	300,000		$	—
Shares issued for conversion of notes payable	$	157,815		$	—
Shares received for cancellation of asset agreement	$	12,000,000		$	—

AND 2022

See accompanying notes to the unaudited consolidated financial statements.

	Nine Months Ended December 31, 2023			Nine Months Ended December 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss for the period	$	(2,865,209	)	$	(1,722,691	)
Adjustments to reconcile net loss to net cash flows used in operating activities
Non cash currency adjustments		—			—
Stock for services		—			802,500
Stock to directors		—			—
Income tax expense for valuation allowance on deferred tax asset		189,355			—
Impairment of intangibles		439,779			—
Shares issued for warrants		—			—
Stock subscriptions delivered		—			136,721
Changes in assets and liabilities:
Funds in attorney trust		—			12,409
Inventory		—			—
VAT receivable		66,637			15,308
Deferred tax asset		—			(142,850	)
Accounts payable		740,284			126,162
Accrued liabilities		55,658			(384,057	)
Net Cash Used by Operating Activities		(1,373,496	)		(1,156,498	)

CASH FLOWS FROM INVESTING ACTIVITIES
Acquisition of intangible assets		—			(18,147	)
Net Cash (Used) Provided by Investing Activities		—			(18,147	)


CASH FLOWS FROM FINANCING ACTIVITIES
Purchase of common shares for cash		(44,064	)		50,280
Shares issued for conversion of debt to equity		544,738			—
Loan from related parties		788,889			1,043,125
Net Cash Provided by Financing Activities		1,289,563			1,093,405

Net change in cash		(83,933	)		(81,240	)

Effect of exchange rate adjustments on cash		77,617			30,240

Cash and cash equivalents, beginning of period		8,890			63,816
Cash and cash equivalents, end of period	$	2,574		$	12,816

NON-CASH INVESTING AND FINANCING INFORMATION
Shares issued for services	$	335,769		$	802,500
Shares issued to directors	$	202,575		$	—
Shares issued for asset acquisition	$	295,000		$	—
Shares issued for exercise of warrants	$	13,500		$	—
Shares issued for conversion of notes payable	$	2,507,339		$	—

~~F-4~~See accompanying notes to financial statements.

~~Table of Contents~~F-4

~~ALTEROLA BIOTECH,~~Table ~~INC.~~of Contents

~~NOTES~~ALTEROLA TOBIOTECH, ~~THE UNAUDITED CONSOIDATED FINANCIAL STATEMENTS~~INC.

~~SEPTEMBER~~NOTES ~~30,~~TO ~~2023~~THE UNAUDITED CONSOIDATED FINANCIAL STATEMENTS

~~NOTE~~DECEMBER 131, ~~– NATURE OF BUSINESS~~2023

~~After~~NOTE ~~formation,~~1 ~~the~~– ~~Company~~NATURE ~~was~~OF ~~in the business of mineral exploration. On May 3~~BUSINESS, ~~2010,~~LIQUIDITY ~~the~~& ~~Company~~GOING sold its mineral exploration business and entered into an Intellectual Property Assignment Agreement (“IP Agreement”) with Soren Nielsen pursuant to which Mr. Nielsen transferred his right, title and interest in all intellectual property relating to certain chewing gum compositions having appetite suppressant activity (the “IP”) to the Company for the issuance of 55,000,000 shares of the Company’s common stock.CONCERN

~~Following~~After formation, the ~~acquisition~~Company ofwas in the IPbusiness of mineral exploration. On May 3, 2010, the Company ~~changed~~sold its mineral exploration business and ~~direction~~entered tointo ~~pursue~~an ~~the~~Intellectual ~~development~~Property ofAssignment ~~chewing~~Agreement ~~gums~~(“IP ~~for~~Agreement”) ~~the~~with ~~delivery~~Soren ofNielsen ~~Nutraceutical/functional ingredients~~pursuant ~~for~~to ~~applications~~which ~~such~~Mr. Nielsen astransferred ~~appetite~~his ~~suppressant~~right, ~~cholesterol~~title and interest in all intellectual property relating to certain chewing gum compositions having appetite suppressant, ~~vitamin~~activity ~~delivery~~(the “IP”) to the Company for the issuance of 55,000,000 ~~antioxidant~~shares ~~delivery~~of ~~and~~the ~~motion sickness~~Company’s ~~suppressant~~common stock.

~~Upon~~Following ~~completion~~the acquisition of the ~~transaction,~~IP the ~~business~~Company ~~plan of the company~~ changed ~~and~~its ~~was~~business nodirection ~~longer~~to ~~focused~~pursue ~~on a chewing gum delivery system. The company re-focused its activities on~~ the development of ~~cannabinoid,~~chewing ~~cannabinoid-like,~~gums ~~and~~for ~~non-cannabinoid~~the ~~pharmaceutical~~delivery ~~active~~of ~~pharmaceutical~~Nutraceutical/functional ingredients ~~(APIs),~~for ~~pharmaceutical~~applications ~~medicines~~such ~~made~~as ~~from~~appetite ~~cannabinoid~~suppressant, ~~cannabinoid-like~~cholesterol suppressant, ~~and~~vitamin ~~non-cannabinoid APIs and European novel food approval of cannabinoid-based~~delivery, ~~cannabinoid-like~~antioxidant ~~and~~delivery ~~non-cannabinoid ingredients~~ and ~~products. In addition, the company plans to develop~~motion ~~such~~sickness ~~bulk ingredients for supply into the cosmetic sector~~suppressant.

On January 19, 2021, the Company entered into aan Stock Purchase Agreement (the “Agreement”) with ABTI Pharma Limited, a company registered in England and Wales (“ABTI Pharma”), pursuant to which the Company agreed to acquire all of the outstanding shares of capital stock of ABTI Pharma from its shareholders in exchange for 600,000,000 shares of the Company pro rata to the ABTI Pharma shareholders. The shares were issued on January 29, 2021 in anticipation of the closing and the parties to the transaction agreed in a March 24, 2021 amendment to close upon the ABTI Pharma Limited Shares being transferred to the Company, which was to occur upon the filing by the Company of its outstanding ~~December~~September 3130, 2020 quarterly report on Form 10-Q, which was filed on May 28, 2021 with the Securities and Exchange Commission. The transaction closed on May 28, 2021.

The transaction was accounted for as a reverse acquisition and recapitalization. ABTI Pharma ~~was~~is the acquirer for accounting purposes and the Company ~~was~~is the issuer. The historical financial statements presented are the financial statements of ABTI. The Agreement was treated as a recapitalization and not as a business combination; at the date of the acquisition, the net liabilities of the legal acquirer, Alterola, were $389,721.

OnThe ~~December~~business 2,plan ~~2021,~~of the ~~Company~~company ~~closed~~isl anno ~~Asset~~longer ~~Purchase~~focused ~~Agreement~~on ~~(the~~a ~~“Purchase~~chewing ~~Agreement”)~~gum ~~with~~delivery C2system ~~Wellness~~but ~~Corp.,~~was are-focused ~~Wyoming~~on the development of cannabinoid, ~~corporation~~cannabinoid-like, and ~~Dr.~~non-cannabinoid G.pharmaceutical ~~Sridhar~~active ~~Prasad~~pharmaceutical ingredients (~~together~~APIs), ~~the~~pharmaceutical ~~“Seller”)~~medicines made from cannabinoid, cannabinoid-like, and ~~acquired~~non-cannabinoid ~~certain~~APIs IPand ~~assets~~European ~~(the~~novel ~~“Assets”)~~food approval of cannabinoid-based, cannabinoid-like and non-cannabinoid ~~from~~ingredients ~~Seller~~and products .In addition, ~~which~~the ~~include:~~company plans to develop such bulk ingredients for supply into the cosmetic sector.

•On December ~~Novel~~2, ~~cannabinoid~~2021, ~~molecules~~the Company closed an Asset Purchase Agreement (the “Purchase Agreement”) with C2 Wellness Corp., a Wyoming corporation, and ~~their~~Dr. ~~associated~~G. ~~intellectual~~Sridhar ~~property;~~Prasad (together, the “Seller”) and acquired certain IP assets (the “Assets”) from Seller, which include:

• Novel cannabinoid ~~pro-drugs,~~molecules and their associated intellectual property;

• Novel ~~proprietary~~ cannabinoid ~~formulations~~pro-drugs, ~~designed to target lymphatic delivery,~~ and their associated intellectual property;

• Novel proprietary ~~nano-encapsulated~~ cannabinoid formulations, indesigned ~~self-dissolving~~to ~~polymers~~target lymphatic delivery, and their associated intellectual property; ~~and~~

• ~~Cannabinoids~~Novel ~~and~~proprietary ~~cannabinoid pro~~nano-~~drug~~encapsulated cannabinoid formulations, ~~for~~in ~~topical~~self-dissolving ~~ocular delivery~~polymers, and their associated intellectual property.; and

F• Cannabinoids and cannabinoid pro-5drug formulations for topical ocular delivery, and their associated intellectual property.

~~Table~~In exchange for the Assets, the Company issued to Seller shares of ~~Contents~~common stock. On September 8, 2023, the Company and Seller entered into an Agreement to sell the assets, such that the Company sold the assets back to the Seller and the Seller paid 29,015,993 shares of ABTI common stock to the Company. The assets were sold to the Seller in September 2023.

~~ALTEROLA~~As ~~BIOTECH~~of July 5, ~~INC~~2023, we acquired intellectual property from Alinova Biosciences Ltd. We acquired Alinova’s joint interest in the patent family of PTX 0001. We paid 35,000 Sterling in cash and 5,000,000 shares of ABTI Stock.

~~NOTES TO THE UNAUDITED CONSOLIDATEDEDFINANCIAL STATEMENTS~~F-5

~~SEPTEMBER 30,~~Table ~~2023~~of Contents

~~NOTE~~ALTEROLA 1BIOTECH, ~~– NATURE OF BUSINESS (CONTINUED)~~INC.

InNOTES ~~exchange~~TO ~~for~~THE ~~the~~UNAUDITED ~~Assets,~~CONSOIDATED ~~the~~FINANCIAL Company issued to Seller shares of common stock. On September 8, 2023, the Company and Seller entered into an Agreement to Return Assets and the shares, such that the Company transferred the Assets back to the Seller and the Seller paid 29,015,993 shares of ABTI common stock to the Company.STATEMENTS

AsDECEMBER ~~of July 5~~31, 2023, we acquired intellectual property from Alinova Biosciences Ltd. We acquired Alinova’s joint interest in the patent family of PTX 0001. We paid 35,000 Sterling in cash and 5,000,000 shares of ABTI stock.

~~NOTE 2~~LIQUIDITY –& ~~SUMMARY~~GOING ~~OF SIGNIFICANT ACCOUNTING POLICIES~~CONCERN

~~Basis~~Alterola has negative working capital of ~~Presentation~~$1,160,035, has incurred losses since inception of $11,946,656, and has not received revenues from sales of products or services. These factors create substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.

The ~~accompanying~~ability ~~consolidated~~of ~~financial~~Alterola ~~statements~~to ~~were~~continue ~~prepared~~as ina ~~accordance~~going ~~with~~concern ~~accounting~~is ~~principles~~dependent ~~generally~~on ~~accepted~~the inCompany generating cash from the ~~United State~~sale of ~~America~~its ~~(GAAP~~common ~~accounting)~~stock and/or obtaining debt financing and attaining future profitable operations. Management’s plans include ~~the~~selling ~~accounts~~its ofequity ~~Alterola~~securities and obtaining ~~its~~debt ~~wholly~~financing ~~owned~~to ~~subsidiaries~~fund ~~ABTI~~its ~~Pharma,~~capital ~~Phytotherapeutix Ltd,~~requirement ~~Ferven~~and ~~Ltd.~~ongoing operations; however, ~~and~~there ~~Nano4M~~can ~~Ltd.~~be ~~All~~no ~~material~~assurance ~~intercompany~~the ~~transactions~~Company ~~and~~will be ~~balances~~successful ~~have~~in ~~been~~these ~~eliminated~~efforts.

~~The~~NOTE ~~Company~~2 ~~had~~– aSUMMARY ~~September~~OF 30SIGNIFICANT ~~fiscal~~ACCOUNTING ~~year end. Subsequent to the Agreement with ABTI Pharma, the Company has changed its year end from September 30 to March 31.~~POLICIES

~~Use~~Basis of ~~Estimates~~Presentation

~~The~~These ~~preparation~~unaudited ofcondensed financial statements inhave ~~conformity~~been ~~with~~prepared ~~GAAP~~in ~~requires~~accordance ~~management~~with toaccounting ~~make~~principles ~~estimates~~generally ~~and~~accepted ~~assumptions~~in ~~that affect~~ the ~~reported~~United ~~amounts~~States of ~~assets~~America (“US GAAP”) and ~~liabilities~~the rules and ~~disclosure~~regulations of ~~contingent~~the ~~assets~~Securities and ~~liabilities~~Exchange atCommission ~~the~~(“SEC”). They ~~date~~include the ~~financial~~accounts ~~statements~~of Alterola and ~~the~~its ~~reported amount~~wholly ofowned ~~revenues~~subsidiaries ~~and~~ABTI ~~expenses~~Pharma, ~~during~~Phytotherapeutix ~~the~~Ltd ~~reporting~~and ~~period~~Ferven Ltd.. ~~Actual~~All ~~results~~material intercompany ~~could~~transactions ~~differ~~and ~~from~~balances ~~those~~have ~~estimates~~been eliminated.

~~Cash~~These financial statements and ~~Equivalents~~the notes attached hereto should be read in conjunction with the financial statements and notes included in the Company’s 10-K for its fiscal year ended March 31, 2023. In the opinion of the Company, all adjustments, including normal recurring adjustments necessary to present fairly the financial position of the Company, as of December 31, 2023, and the results of its operations and cash flows for the three and nine months then ended have been included. The results of operations for the interim period are not necessarily indicative of the results for the full year ending March 31, 2024.

~~For~~The ~~purposes~~Company ofhad ~~the~~a ~~statement~~September of30 ~~cash~~fiscal ~~flows,~~year ~~the~~end. ~~Company~~Subsequent ~~considers~~to ~~highly~~the ~~liquid~~Agreement ~~financial~~with ~~instruments~~ABTI ~~purchased~~Pharma, ~~with~~the aCompany ~~maturity~~has ofchanged ~~three months~~its oryear ~~less~~end tofrom beSeptember 30 ~~cash~~to ~~equivalents~~March 31.

~~Fair~~Use ~~Value~~ of ~~Financial Instruments~~Estimates

~~Alterola’s~~The preparation of financial ~~instruments~~statements ~~consist~~in ofconformity ~~cash~~with ~~and~~GAAP ~~equivalents,~~requires ~~accrued~~management ~~expenses,~~to ~~accrued~~make ~~interest~~estimates and ~~notes~~assumptions ~~payable.~~that ~~The~~affect ~~carrying~~the ~~amount~~reported amounts of ~~these financial~~assets ~~instruments~~and ~~approximates~~liabilities ~~fair~~and ~~value~~disclosure ~~(“FV”)~~of ~~due~~contingent ~~either~~assets toand ~~length~~liabilities ofat ~~maturity~~the ordate ~~interest~~the ~~rates~~financial ~~that~~statements ~~approximate~~and the reported ~~prevailing~~amount ~~market~~of ~~rates~~revenues ~~unless~~and ~~otherwise~~expenses ~~disclosed~~during inthe ~~these~~reporting ~~financial~~period. ~~statements~~Actual results could differ from those estimates.

FVCash ~~is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date~~ and in the principal or most advantageous market for that asset or liability. The FV should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the FV of liabilities should include consideration of non-performance risk including our own credit risk.Equivalents

~~F-6~~For purposes of the statement of cash flows, the Company considers highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents.

~~Table~~Fair Value of ~~Contents~~Financial Instruments

~~ALTEROLA~~Alterola’s ~~BIOTECH~~financial instruments consist of cash and equivalents, ~~INC~~accrued expenses, accrued interest and notes payable. The carrying amount of these financial instruments approximates fair value (“FV”) due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements.

~~NOTES~~FV TOis ~~THE~~defined ~~UNAUDITED~~as ~~CONSOLIDATEDEDFINANCIAL~~the ~~STATEMENTS~~price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The FV should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the FV of liabilities should include consideration of non-performance risk including our own credit risk.

~~SEPTEMBER 30, 2023~~F-6

~~NOTE 2~~Table –of ~~SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)~~Contents

~~Fair Value~~ALTEROLA ofBIOTECH, ~~Financial Instruments (continued)~~INC.

~~In addition~~NOTES toTO ~~defining~~THE ~~FV,~~UNAUDITED ~~the~~CONSOLIDATED ~~disclosure~~FINANCIAL requirements around FV establish a FV hierarchy for valuation inputs which is expanded. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring FV are observable in the market. Each FV measurement is reported in one of the three levels which is determined by the lowest level input that is significant to the FV measurement in its entirety. These levels are:STATEMENTS

~~Level 1~~DECEMBER –31, ~~inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.~~2023

~~Level~~ NOTE 2 – ~~inputs~~SUMMARY ~~are~~OF ~~based~~SIGNIFICANT ~~upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for~~ACCOUNTING ~~identical~~POLICIES or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.(CONTINUED)

~~Level~~In 3addition –to ~~inputs~~defining ~~are~~FV, ~~generally~~the ~~unobservable~~disclosure ~~and~~requirements ~~typically~~around ~~reflect~~FV ~~management’s~~establish ~~estimates~~a ofFV ~~assumptions~~hierarchy ~~that~~for ~~market~~valuation ~~participants~~inputs which is expanded. The hierarchy ~~would~~prioritizes ~~use~~the ininputs ~~pricing~~into three levels based on the ~~asset~~extent orto ~~liability.~~which ~~The~~inputs used in measuring FV are ~~therefore~~observable in the market. Each FV measurement is reported in one of the three levels which is determined ~~using~~by ~~model-based~~the ~~techniques~~lowest ~~that~~level ~~include~~input ~~option~~that ~~pricing models,~~is ~~discounted~~significant ~~cash~~to ~~flow~~the ~~models,~~FV ~~and~~measurement in ~~similar~~its ~~techniques~~entirety. These levels are:

~~The~~Level ~~carrying~~1 ~~value~~– ofinputs ~~the Company’s financial assets and liabilities which consist of cash, accounts payable and accrued liabilities, and notes payable~~ are ~~valued~~based ~~using~~upon ~~level~~unadjusted 1quoted ~~inputs.~~prices ~~The~~for ~~Company~~identical ~~believes that the recorded values approximate their FV due to the short maturity of such~~ instruments. ~~Unless~~traded ~~otherwise~~in ~~noted,~~active ~~it is management’s opinion that the Company is not exposed to significant interest, exchange or credit risks arising from these financial instruments~~markets.

~~Income~~Level ~~Taxes~~2 – inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

~~Income~~Level ~~taxes~~3 ~~are~~– ~~computed~~inputs ~~using~~are ~~the~~generally ~~asset~~unobservable and ~~liability~~typically ~~method.~~reflect ~~Under~~management’s ~~the~~estimates ~~asset~~of ~~and~~assumptions ~~liability~~that ~~method,~~market ~~deferred income tax assets and liabilities~~participants ~~are~~would ~~determined~~use ~~based~~in onpricing the ~~differences~~asset ~~between~~or ~~the~~liability. ~~financial~~The ~~reporting~~FV ~~and tax bases of assets and liabilities and~~ are ~~measured~~therefore determined using ~~the~~ ~~currently~~model-based ~~enacted~~techniques ~~tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets~~ that, ~~based~~include onoption ~~available~~pricing ~~evidence~~models, ~~are~~discounted ~~not~~cash ~~expected~~flow tomodels, beand ~~realized~~similar techniques.

~~Foreign~~The ~~Currency~~carrying ~~Translation~~value of the Company’s financial assets and liabilities which consist of cash, accounts payable and accrued liabilities, and notes payable are valued using level 1 inputs. The Company believes that the recorded values approximate their FV due to the short maturity of such instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, exchange or credit risks arising from these financial instruments.

The financial statements are presented in US Dollars. Transactions with foreign subsidiaries where US dollars are not the functional currency will be recorded in accordance with Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 830 Foreign Currency Transaction. According to Topic 830, all assets and liabilities are translated at the exchange rate on the balance sheet date, stockholders’ equity is translated at historical rates and statement of operations items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) in accordance with ASC Topic 220, Comprehensive Income~~. Gains and losses resulting from the translations of foreign currency transactions and balances are reflected~~ ~~in the statement of operations and comprehensive income (loss)~~Taxes

~~Revenue~~Income ~~Recognition~~taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

OnForeign ~~January~~Currency 1,Translation 2018, the Company adopted ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"), using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under ASC 605. As of and for the year ended March 31, 2023, the financial statements were not materially impacted as a result of the application of Topic 606 compared to Topic 605.

~~F-7~~The financial statements are presented in US Dollars. Transactions with foreign subsidiaries where US dollars are not the functional currency will be recorded in accordance with Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 830 Foreign Currency Transaction. According to Topic 830, all assets and liabilities are translated at the exchange rate on the balance sheet date, stockholders’ equity is translated at historical rates and statement of operations items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) in accordance with ASC Topic 220, Comprehensive Income. Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the statement of operations and comprehensive income (loss).

~~Table of Contents~~Revenue Recognition

~~ALTEROLA~~On ~~BIOTECH~~January 1, ~~INC~~2018, the Company adopted ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"), using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under ASC 605. As of and for the year ended December 31, 2022, the financial statements were not materially impacted as a result of the application of Topic 606 compared to Topic 605.

~~NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~F-7

~~SEPTEMBER 30,~~Table ~~2023~~of Contents

~~NOTE~~ALTEROLA 2BIOTECH, ~~– SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)~~INC.

~~Loss~~NOTES ~~Per~~TO ~~Common~~THE ~~Share~~UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

~~Basic~~DECEMBER loss per share is calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share includes potentially dilutive securities such as outstanding options and warrants31, using various methods such as the treasury stock or modified treasury stock method in the determination of dilutive shares outstanding during each reporting period. The Company does not have any potentially dilutive instruments.2023

~~Stock-Based~~NOTE ~~Compensation~~2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

~~Stock-based~~Loss ~~compensation~~Per isCommon ~~accounted for at FV in accordance with ASC Topic 718. To date, the Company has not adopted a stock option plan and has not granted any stock options~~Share

~~Research~~Basic loss per share is calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share includes potentially dilutive securities such as outstanding options and ~~development~~warrants, using various methods such as the treasury stock or modified treasury stock method in the determination of dilutive shares outstanding during each reporting period. The Company does not have any potentially dilutive instruments.

~~We engage in a variety of research and development~~Stock-Based activities to develop our technologies and work toward development of a saleable product. When it is determined that the research and development products we are creating have reached a point where saleable products are possible, these amounts are capitalized. As of September 30, 2023 and March 31 ,2023 there are no capitalized research and development costs.Compensation

~~The~~Stock-based ~~research~~compensation ~~and~~is ~~development~~accounted ~~costs~~for ~~incurred~~at byFV ~~the~~in ~~company~~accordance ~~relate~~with toASC Topic 718. To date, the ~~following:~~Company has not adopted a stock option plan and has not granted any stock options

~~• Licenses for patent~~ Research and ~~know-how (Nano 4 M)- this relates to the company’s formulation of Active Pharmaceutical Ingredients ( API) for its lead pharmaceutical programs.~~development

•We ~~Protein~~engage ~~Technologies~~in ~~/Bright~~a ~~Bio/Equipped~~variety 4of –research ~~this~~and ~~relates~~development activities to ~~the~~develop ~~company’s~~our ~~research~~technologies ~~into~~and ~~production~~work oftoward ~~cannabinoids~~development byof ~~biosynthesis~~a ~~(as~~saleable ~~opposed~~product. toWhen ~~botanical~~it ~~production~~is bydetermined ~~growing~~that ~~plants).~~the ~~The~~research ~~company~~and development ~~has~~products ~~genetically~~we ~~modified~~are ancreating ~~organism~~have toreached ~~produce~~a ~~cannabinoids~~point bywhere ~~fermentation~~saleable ~~(similar~~products toare ~~methodology~~possible, ~~used~~these ~~for~~amounts ~~the~~are ~~production~~capitalized. As of ~~antibiotics)~~December 31, 2023 and March 31 ,2023 there are no capitalized research and development costs.

•The ~~Apex~~research ~~Molecular~~and ~~Ltd.- the company has a number of pharmaceutical~~ development ~~programs~~costs ~~using~~incurred ~~both~~by ~~novel~~the company ~~and~~relate ~~natural molecules. The Company employs third party chemistry/ contract, manufacturing companies such as Apex Molecular Ltd.~~ to ~~synthesize~~the ~~and purify these compounds for their pharmaceutical development programs.~~following:

• Licenses for patent and know-how ( Nano 4 M) - this relates to the company’s formulation of Active Pharmaceutical Ingredients ( API) for its lead pharmaceutical programs. • Protein Technologies Ltd – this relates to the company’s research into production of cannabinoids by biosynthesis (as opposed to botanical production by growing plants). The company has genetically modified an organism to produce cannabinoids by fermentation ( similar to methodology used for the production of antibiotics) • Apex Molecular Ltd.- the company has a number of pharmaceutical development programs using both novel and natural molecules. The Company employs third party chemistry / contract, manufacturing companies such as Apex Molecular Ltd. to synthesize and purify these compounds for their pharmaceutical development programs. • Acquisition of intellectual property from Alinova Biosciences Ltd. • Continued patent prosecution and internationalization of company intellectual property. • Staff costs and consultancy costs relating to R & D.

•Other Intangible ~~Continued patent prosecution and internationalization of company intellectual property.~~Assets

•We have ~~Staff~~recorded ~~costs~~the assets acquired as part of the C2 Wellness acquisition as indefinite lived Intangible assets. Indefinite life intangible assets recorded are not amortized and, ~~consultancy~~as ~~costs~~a ~~related~~result, toare ~~R&D~~assessed for impairment at least annually, using either a qualitative or quantitative process. We performed this annual assessment as of March 31, 2023, noting no factors indicating possible impairment of intangible assets recognized.

~~Other~~Risks ~~Intangible~~and ~~Assets~~Uncertainties

WeOn ~~have~~January ~~recorded~~30, 2020, the ~~assets~~World ~~acquired~~Health asOrganization ~~part~~declared the coronavirus outbreak a “Public Health Emergency of ~~the~~International C2Concern” and ~~Wellness~~on ~~acquisition~~March as10, ~~indefinite~~2020, ~~lived~~declared ~~Intangible~~it ~~assets~~to be a pandemic. Actions ~~Indefinite~~taken ~~life~~around ~~intangible assets~~the ~~recorded~~world ~~are~~to ~~not~~help ~~amortized~~mitigate ~~and~~the spread of the coronavirus include restrictions on travel, asand aquarantines ~~result~~in certain areas, ~~are~~and ~~assessed~~forced closures for ~~impairment~~certain attypes ~~least~~of ~~annually,~~public ~~using~~places ~~either~~and abusiness. The ~~qualitative~~Coronavirus orand ~~quantitative process.~~actions Wetaken ~~performed~~to ~~this~~mitigate ~~annual~~it ~~assessment~~have ashad and are expected to have an adverse impact on the economies and financial markets of ~~March~~many 31countries, ~~2023,~~including ~~noting~~the nogeographical ~~factors~~area ~~indicating~~in ~~possible~~which ~~impairment~~the ofCompany ~~intangible~~plans ~~assets recognized~~to operate.

Recent Accounting Pronouncements

Alterola does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

F-8

Table of Contents

ALTEROLA BIOTECH, INC.

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

~~SEPTEMBER 30~~DECEMBER 31, 2023

NOTE 3 – ACCRUED EXPENSES

Accrued expenses consisted of the following at ~~September~~December 3031, 2023 and March 31, 2023

	September 30, 2023		March 31,2023
	December 31, 2023		March 31,2023
Audit fees	$	~~5,500~~—	$	15,000
Accounting		7,~~955~~407		7,407
Research and development		9,433		9,433
General and administrative		106,~~847~~014		115,821
Legal fees and transfer agent		~~116~~187,~~635~~668		107,203
Total Accrued Expenses	$	~~246~~310,~~370~~522	$	254,864

NOTE 4 – CAPITAL STOCK

The Company has 2,000,000,000 shares of $0.001 par value common stock authorized and 10,000,000 shares of $0.001 par value preferred stock authorized.

~~During~~On ~~September~~August 11, 2021, the Company ~~received~~issued ~~an investment for £100~~15,000 ~~Sterling (or $137~~,~~627)~~000 inwarrants ~~exchange~~to ~~for~~purchase acommon ~~subscription~~stock ~~for~~at ~~280,000~~$0.64 ~~shares~~per share. OnThe ~~May~~warrants 2,were ~~2022,~~issued ~~the~~with ~~Company~~a ~~issued the~~5 ~~280,000 shares~~year ~~to the investor~~term. On The ~~May~~warrants 4,exercise ~~2022,~~price includes ~~the~~a ~~Company~~declining ~~issued~~scale ~~2,250,000 shares~~with tothe astock ~~director~~price. asAs ~~part~~ of December 31, 2022, the ~~employment contract~~warrants were exercisable at $0.~~214~~001 per share, orand ~~$481,500. On~~the total ~~August~~potential 1,impact ~~2022,~~ on the ~~Company~~financial ~~entered~~statements ~~into~~of ~~agreements~~the ~~for~~exercise ~~a total~~ of ~~$75,000~~the USwarrants ~~Dollars.~~was Aapproximately ~~total~~$1 ofmillion ~~2,250,000~~dollars. The warrants ~~shares~~ were ~~issued~~exercised toon ~~note~~June ~~holders~~13, in2023 ~~connection with~~(see ~~these~~below). ~~loan~~The ~~agreements.~~total ~~See~~potential ~~Note~~impact 5.on ~~These~~the ~~loans~~financial ~~were~~statements ~~repaid~~of inthe ~~full~~exercise byof ~~December~~the ~~23,~~warrants was ~~2022~~approximately $13,500.

~~On August~~During ~~11,~~ September 2021, the Company ~~issued~~received ~~15,000,000~~an ~~warrants~~investment tofor ~~purchase~~£100,000 ~~common~~Sterling ~~stock~~(or at $~~0.64 per share. The warrants were issued with a~~136,721) 5in ~~year~~exchange ~~term. The~~for ~~warrants exercise price includes~~ a ~~declining~~subscription ~~scale~~for ~~with~~280,000 ~~the stock price~~shares. AsOn ofMay ~~December 31~~2, 2022, the ~~warrants were~~Company ~~exercisable~~issued ~~at $0.001 per share and~~ the ~~total~~280,000 ~~potential~~shares ~~impact~~to on the ~~financial statements of the exercise of the warrants was approximately $1 million dollars.~~ investor

On ~~April~~October 529, ~~2022~~2021, the ~~company~~Company issued ~~384~~7,~~615~~500,000 shares ~~to an investor for an investment~~ of ~~$50,000~~stock ~~(at~~in aexchange ~~price~~for ofservices ~~$0.13~~provided ~~per~~byEMC2 ~~share)~~Capital. ~~On April~~ ~~29,~~The ~~2022,~~shares ~~the~~were ~~Company~~ issued at ~~1,500,000~~fair ~~shares~~value ~~for~~of ~~services~~the ~~under~~date aof ~~consultancy agreement at $0.214 per share~~exchange, or $~~321~~2,~~000~~399,250.

As ofpursuant ~~September~~to 30the asset purchase agreement dated November 9, ~~2023~~2021, the ~~warrants~~Company ~~were~~acquired ~~exercisable~~certain intellectual property rights of C2 Wellness Corp. In exchanges for the assets acquired, the Company issued 24,000,000 shares of common stock valued at $0.~~001~~ 50 per share. ~~and~~The ~~the~~intellectual ~~total~~property ~~potential~~rights ~~impact~~acquired are onrecorded ~~the~~as ~~financial~~intangible ~~statements~~assets ~~of the~~as ~~exercise~~ of ~~the~~December ~~warrants~~31, ~~was~~2021 ~~approximately~~for $1512,000,000.

On ~~October~~December 2921, 2021, the ~~Company~~company issued 7520,~~500,~~000 shares of stock in exchange for ~~services provided by EMC2 Capital. The shares were issued at fair value of the date of exchange, or~~ $2130,399,250. As pursuant to the asset purchase agreement dated November 9, 2021, the Company acquired certain intellectual property rights of C2 Wellness Corp. In exchanges for the assets acquired, the Company issued 24,000~~,000 shares~~ of ~~common~~cash ~~stock valued at $0~~consideration.50 per share. The intellectual property rights acquired are recorded as intangible assets as of December 31, 2021 for $12,000,000. These assets were disposed of in an agreement dated September 8, 2023 in exchange of 29,015,993 ABTI shares being returned to Treasury.

On or ~~about~~February ~~March 3~~8, 2022, the company ~~Company~~ issued 16333,~~000,000~~333 shares ofto ~~stock~~an investor for ~~services~~an ~~under~~investment aof ~~consulting~~$50,000 ~~agreement. The shares were issued~~ (at ~~fair~~a ~~value~~price ~~the date~~ of ~~the~~$0.15 ~~exchange,~~per ~~or $3,360,000~~share).

On ~~June~~ 6or about March 3, ~~2023~~2022, the Company ~~reclaimed~~issued 4416,~~064~~000,000 shares ~~into~~of ~~Treasury~~stock for services under a consulting agreement. The shares were issued at fair value the date of the exchange, or $3,360,000.

On ~~June~~ 13April 5, ~~2023~~2022, wethe company issued 13384,~~500,000~~615 shares ~~of common stock~~ to ~~EMC2~~an ~~Capital~~investor ~~LLC~~for ~~following~~an ~~the~~investment ~~cashless exercise~~ of ~~their 15~~$50,000~~,000~~ ~~Warrants issued~~(at ina ~~August~~price ~~2021~~of $0.13 per share).

~~F-9~~On April 29, 2022, the Company issued 1,500,000 shares for services under a consultancy agreement at $0.214 per share, or $321,000.

~~Table~~On May 2, 2022, the Company issued 280,000 shares to an investor relating to a subscription agreement for an investment of ~~Contents~~£100,000 Sterling (or $136,721) at $0.50 per share, or $140,000.

~~ALTEROLA~~On May 4, 2022, we issued ~~BIOTECH~~2,250,000 ~~INC~~shares of our common stock to our director, Mr. Michael Hunter Land, pursuant to his employment agreement dated October 18, 2021 and board decision to award him shares for his performance.

~~NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS~~F-9

~~SEPTEMBER 30,~~Table ~~2023~~of Contents

~~NOTE~~ALTEROLA 4BIOTECH, ~~– CAPITAL STOCK (CONTINUED)~~INC.

OnNOTES ~~June~~TO ~~13,~~THE ~~2023,~~UNAUDITED weCONSOLIDATED ~~issued~~FINANCIAL ~~476,000 shares of common stock to Alison Rose Burgess as settlement of a £125,000 Sterling loan under the terms and conditions of the loan dated 21 September 2021.~~STATEMENTS

OnDECEMBER ~~June 13~~31, 2023~~, we issued 5,000,000 shares of common stock to Alinova Biosciences Ltd as part payment of consideration for the acquisition of intellectual property.~~

~~On June 13, 2023, we issued~~NOTE ~~5,999,900~~4 ~~shares~~– ofCAPITAL ~~common~~STOCK ~~stock to Long Eight Limited as part payment of consideration for services received by Green Ocean Administration Limited.~~(CONTINUED)

On June 136, 2023, wethe ~~issued 10~~Company reclaimed 44,~~088~~064,~~100~~000 shares ofinto ~~common stock to Warren Law Group to be held in escrow as potential part payment for services received from Bridgeway Capital Partners LLC, Bridgeway Capital Partners II LLC and Entoro Securities LLC~~Treasury.

On June 1413, 2023, we issued 9 13,~~000~~500,000 shares of common stock to ~~our~~EMC2 ~~Directors~~Capital asLLC ~~payment~~following ~~for~~the cashless exercise of their ~~services~~15,000,000 asWarrants issued ~~Directors~~in August 2021.

~~Finally,~~On June ~~on September 8~~13, 2023, ~~the~~we ~~Company~~issued ~~entered~~476,000 ~~into~~shares anof ~~Agreement~~common stock to ~~Return~~Alison ~~Assets~~Rose ~~and~~Burgess ~~Shares~~as ~~with~~settlement ~~C2 Wellness Corp. As part~~ of ~~the~~a ~~agreement~~£125,000 ~~the~~Sterling ~~company~~loan under ~~received~~the ~~29,015,993~~terms ~~shares of ABTI stock~~ and ~~returned~~conditions ~~all~~of ~~assets related to~~ the ~~acquisition,~~loan ~~resulting~~dated in21 aSeptember ~~write-off of $12,000,000 in intangibles~~2021.

~~The~~On ~~Company~~June ~~had~~13, ~~778~~2023,~~031,955 and 807,047,948~~ ~~shares~~we ~~of common stock~~ issued ~~and outstanding as of September 30~~5, ~~2023 and March 31~~000,000 ~~2023, respectively. There are no~~ shares of ~~preferred~~common stock ~~issued~~to ~~and~~Alinova ~~outstanding~~Biosciences Ltd as ofpart ~~September~~payment ~~30,~~of ~~2023~~consideration ~~and~~for ~~March~~the ~~31,~~acquisition of ~~2023~~intellectual property.

~~NOTE~~June 13, 2023, we issued 5,999,900 –shares ~~NOTES~~of ~~PAYABLE~~common stock to Long Eight Limited as part payment of consideration for services received by Green Ocean Administration Limited.

OnJune ~~August 1~~13, ~~2022~~2023, ~~the~~we ~~Company~~ issued a10,088,100 ~~note~~shares ~~payable for 90 days bearing zero interest for the term~~ of ~~the~~common ~~note,~~stock ~~for~~to ~~cash~~Warren ~~received~~Law byGroup ~~the Company~~to onbe ~~June~~held ~~29,~~in ~~2022~~escrow ~~and~~as ~~July~~potential ~~18, 2022 totaling $75,000. As~~ part ofpayment ~~the~~for ~~note the Company committed delivery of 2,250,000 shares~~services toreceived ~~the~~from ~~noteholders.~~Bridgeway ~~The~~Capital ~~loans~~Partners ~~totaling $75~~LLC,~~000~~ ~~were~~Bridgeway ~~repaid~~Capital inPartners ~~full~~II byLLC ~~December~~and ~~23,~~Entoro ~~2022~~Securities LLC.

~~NOTE~~On 6June –14, ~~RELATED~~2023, ~~PARTY~~we ~~TRANSACTIONS~~issued 9,000,000 shares of common stock to our Directors as payment for their services as Directors.

~~Alterola~~On ~~neither~~September ~~owns~~8, ~~nor~~2023, ~~leases~~the ~~any~~Company ~~real~~entered orinto ~~personal~~an ~~property.~~Agreement Anto ~~officer~~Return ~~has~~Assets ~~provided~~and ~~office~~Shares ~~space~~with ~~without~~C2 ~~charge~~Wellness Corp. ~~There~~As ispart noof ~~obligation~~the ~~for~~agreement, the ~~officer~~company toreceived ~~continue~~29,015,993 shares ~~this~~of ~~arrangement.~~ABTI ~~Such~~stock ~~costs~~(24,000,000 ~~are~~shares ~~immaterial~~originally issued ~~to the financial statements~~ and ~~accordingly~~5,015,996 ~~are~~shares ~~not~~additionally ~~reflected~~issued) ~~herein. The officers~~ and ~~directors~~sold ~~are~~all ~~involved~~assets inrelated ~~other~~to ~~business~~the ~~activities~~acquisition, ~~and~~resulting ~~most likely will become involved~~ in ~~other~~a ~~business~~write-off ~~activities~~of $12,000,000 in ~~the future~~intangibles.

~~During~~On ~~the~~October ~~period ended September 30~~16, 2023, athe ~~shareholder~~Company ~~made~~issued ~~advances~~587,499,996 toshares ~~the~~in ~~company~~exchange toof ~~fund~~forgiveness ~~operating~~of ~~expenses~~debt inof ~~the~~approximately ~~amount~~$2.35 ofmillion ~~$1,550,737~~outstanding. ~~These~~The ~~advances~~exchange ~~are~~resulted ~~non~~in –a ~~interest~~loss ~~bearing~~on ~~and~~exchange ~~have no specified terms~~ of ~~repayment~~$406,575.

~~F-10~~On December 21, 2023, the Company issued 17,131,001 shares in exchange for services provided for the company for the period ended December 31, 2023, valued at $61,672 at the date of issuance.

~~Table~~The Company has 1,382,662,952 and 807,047,948 shares of ~~Contents~~common stock issued and outstanding as of December 31, 2023 and March 31, 2023, respectively. There are no shares of preferred stock issued and outstanding as of December 31, 2023 and March 31, 2023. The Company had 807,047,948 and 802,913,333 shares of common stock issued and outstanding as of December 31, 2022 and March 31, 2022, respectively. There are no shares of preferred stock issued and outstanding as of December 31, 2022 and March 31, 2022.

~~ALTEROLA~~NOTE ~~BIOTECH,~~5 ~~INC.~~– NOTES PAYABLE

~~NOTES~~On TOAugust ~~THE~~1, ~~UNAUDITED~~2022, ~~CONSOLIDATED~~the ~~FINANCIAL~~Company ~~STATEMENTS~~issued a note payable for 90 days bearing zero interest for the term of the note, for cash received by the Company on June 29, 2022 and July 18, 2022 totaling $75,000. As part of the note the Company committed delivery of 2,250,000 shares to the note holders. The loans totaling $75,000 were repaid in full by December 23, 2022.

~~SEPTEMBER 30, 2023~~F-10

~~NOTE 7~~Table –of ~~LIQUIDITY & GOING CONCERN~~Contents

~~Alterola has negative working capital of $2,322,023,~~ALTEROLA ~~has an accumulated deficit of $10~~BIOTECH,~~431,134, and~~ ~~has not received revenues from sales of products or services~~INC. These factors create substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.

~~The~~NOTES ~~ability~~TO ofTHE ~~Alterola~~UNAUDITED toCONSOLIDATED ~~continue~~FINANCIAL as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.STATEMENTS

~~NOTE~~DECEMBER 831, ~~– SUBSEQUENT EVENTS~~2023

InNOTE ~~accordance~~6 ~~with~~– ~~ASC~~RELATED ~~Topic~~PARTY 855-10, the Company analyzed its operations subsequent to September 30, 2023 to the date these financial statements were issued, and determined it does not have any material subsequent events to disclose in these financial statements, except as noted below.TRANSACTIONS

~~On October~~Alterola ~~16,~~neither ~~2023,~~owns ~~TPR~~nor ~~Global~~leases ~~Limited,~~any ~~Equipped~~real 4or ~~Holdings~~personal property. ~~Limited~~An ~~and~~officer ~~Phytotherapeutix~~has ~~Holdings~~provided ~~Ltd~~office ~~converted~~space aas ~~total~~an ofarms $2length transaction with rental at commercial rates.~~35m~~ ~~USD~~There ofis no obligation for ~~debt~~the inofficer ~~Alterola~~to ~~Biotech~~continue ~~Inc~~this arrangement. ~~(the~~Such ~~“Company”)~~costs ~~into~~are ~~common~~immaterial ~~shares~~to atthe afinancial ~~price~~statements ofand $0accordingly are not reflected herein.~~004~~ The ~~per~~officers ~~share~~and directors are involved in other business activities and most likely will become involved in other business activities in the future.

~~F-11~~During the period ended December 31, 2023, a shareholder made advances to the company to fund operating expenses in the amount of $244,061. These advances are non – interest bearing and have no specified terms of repayment.

~~Table~~NOTE 7 of– ~~Contents~~SUBSEQUENT EVENTS

~~Item~~In accordance 2.with ~~Management’s~~ASC ~~Discussion~~Topic ~~and~~855-10, ~~Analysis~~the ofCompany ~~Financial~~analyzed ~~Condition~~its operations subsequent to December 31, 2023 to the date these financial statements were issued, and ~~Results~~determined ofit ~~Operations~~does not have any material subsequent events to disclose in these financial statements, except as noted below.

~~Forward~~F-~~Looking Statements~~11

~~Certain~~Table statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of ~~the Private Securities Litigation Reform Act of 1995, Section~~Contents 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse affect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

~~Overview~~Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

~~Recent Developments~~Forward-Looking Statements

OnCertain ~~August~~statements, 26other than purely historical information, including ~~2022~~estimates, weprojections, ~~entered~~statements ~~into~~relating ato ~~letter~~our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of ~~intent~~the Private Securities Litigation (Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “~~LOI~~believes,”) ~~dated~~“project,” ~~August~~“expects,” “anticipates,” 25“estimates,” ~~2022~~“intends,” ~~with~~“strategy,” ~~Bright~~“plan,” ~~Green~~“may,” “will,” ~~Corporation~~“would,” (“~~Bright~~will ~~Green~~be,”) “will continue,” a“will ~~Delaware~~likely ~~corporation~~result,” ~~with~~and similar aexpressions. We ~~binding~~intend ~~provision~~such forward-looking statements to be covered by the safe-harbor provisions for ~~Bright~~forward-looking ~~Green~~statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to ~~acquire~~risks and auncertainties ~~25%~~which ~~interest~~may ~~(the~~cause ~~“Share~~actual ~~Purchase”)~~results into ~~our~~differ ~~company~~materially from ~~existing~~the ~~shareholders~~forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse affect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in ~~exchange~~economic ~~for~~conditions, $4legislative/regulatory changes,~~000~~ availability of capital,~~000~~ ~~(the~~interest ~~“Purchase~~rates, ~~Price”)~~competition, and generally accepted accounting principles. ~~The~~These ~~LOI~~risks and uncertainties should also ~~has~~be aconsidered ~~non~~in evaluating forward-~~binding~~looking ~~option~~statements ~~for~~and ~~Bright~~undue ~~Green~~reliance should not be placed on such statements. We undertake no obligation to ~~acquire~~update ~~all~~or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our ~~outstanding~~business, ~~capital~~including ~~stock~~additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

A Share Purchase Agreement was executed on October 3, 2022 and the Purchase Price was divided equally among the following shareholder companies for their shares, controlled by affiliates of our company namely: Phyotherapeutix Holdings Ltd (Colin Stott), Equipped4 Holdings Limited (Dominic Schiller) and TPR Global Limited (Timothy Rogers). These shareholder affiliates, through their respective companies, have committed to enter into loan agreements with our company to provide up to $4,000,000 USD of working capital, subject to the terms and conditions of the signed SPA dated October 03, 2022 being fulfilled. To date, these shareholder affiliates have only received a total of $2,350,000 USD. In accordance with the terms of the loan agreements, the shareholder affiliates had the right to call in the loans from the maturity date (June 03, 2023).Overview

~~The non-binding option has expired for Bright Green~~Our to acquire our company and the parties have not been able to reach a new agreement. As a result, we are no longer in discussions with Bright Green for a potential acquisition, and Mr. Rahif, brought on as a board member for the transaction, has departed the company.Business

~~Additionally,~~Our asgoal ais ~~result~~to ofprovide better medicines for patients around the ~~recent~~world. ~~sale~~We ofbelieve in harnessing the ~~assets~~ therapeutic potential of cannabinoids and ~~intellectual~~cannabinoid- ~~property~~like ~~back~~compounds, which can be developed into valuable treatments to C2seriously ~~Wellness~~ill ~~Corp~~patients. Rather than just focusing on ~~September~~one 8method of identifying, ~~2023~~researching and developing such medicines, C2we ~~Wellness~~are ~~Corp.~~interested ~~has~~in ~~now~~developing ~~regained~~new ~~the~~medicines ~~following~~from ~~assets and~~all ~~intellectual~~sources ~~property:~~including botanical, traditional chemical synthesis and biosynthetic methodologies.

§On ~~Novel~~May ~~cannabinoid~~28, ~~molecules~~2021, we acquired ABTI Pharma Limited, a company registered in England and ~~their~~Wales ~~associated~~(“ABTI ~~intellectual~~Pharma”), ~~property;~~with the purchase of all of its capital stock in exchange for 600,000,000 shares of our common stock pro rata to the ABTI Pharma shareholders.

§As ~~Novel~~a ~~cannabinoid~~result ~~pro-drugs~~of the acquisition, we are a pharmaceutical company working with cannabinoid and ~~their~~cannabinoid ~~associated~~like ~~intellectual~~molecules. ~~property;~~We have three areas of focus:

§1) ~~Novel~~Development ~~proprietary~~of ~~cannabinoid~~regulated ~~formulations,~~pharmaceuticals ~~designed~~(human toand ~~target~~animal ~~lymphatic~~health) ~~delivery,~~ and ~~their~~regulated ~~associated~~food ~~intellectual~~products. ~~property~~This has been achieved via the strategic acquisition of Phytotherapeutix Ltd.;

§2) ~~Novel~~Production ~~proprietary~~of ~~nano-encapsulated~~low ~~cannabinoid~~cost ~~formulations,~~of ingoods ~~self~~Active ~~dissolving~~Pharmaceutical ~~polymers,~~Ingredient (API) and ~~their~~food-grade ~~associated~~ingredients ~~intellectual~~(supported ~~property~~by the strategic acquisition of Ferven Ltd); and

§3) ~~Cannabinoids~~Formulation, and ~~cannabinoid pro-~~drug ~~formulations~~delivery, ~~for~~providing ~~topical~~improved ~~ocular delivery~~bioavailability, solubility and ~~their~~stability ~~associated~~(supported ~~intellectual~~by ~~property~~the exclusive licensing of IP and technology from Nano4M Ltd).

Table of Contents

~~Our~~Phytotherapeutix Ltd, a subsidiary of ABTI Pharma ~~Business~~ Ltd, has generated a number of molecules with patents pending, some of which have demonstrable pharmacological activity, similar to that of CBD. This means that some of these molecules are anticipated to have a similar market potential to CBD across a range of therapeutic areas.

~~Our~~Ferven ~~goal~~Ltd, isanother tosubsidiary ~~provide~~of ~~better~~ABTI ~~medicines~~Pharma ~~for patients~~Ltd, ~~around~~is ~~the~~looking ~~world.~~to Weproduce ~~believe~~cannabinoids inby ~~harnessing~~fermentation. ~~the~~The ~~therapeutic~~exclusively ~~potential~~licensed oforganism ~~cannabinoids~~has ~~and~~the ~~cannabinoid-~~potential ~~like~~to ~~compounds, which can~~ be ~~developed into~~genetically ~~valuable~~modified ~~treatments~~ to produce ~~seriously~~multiple ~~ill~~cannabinoids ~~patients.~~at ~~Rather~~an ~~than~~anticipated ~~just~~very ~~focusing~~low oncost ~~one method~~ of ~~identifying,~~goods. ~~researching~~It ~~and~~is ~~developing such~~anticipated ~~medicines,~~that wethe ~~are~~selected ~~interested~~genetically inmodified ~~developing~~organisms will ~~new~~grow ~~medicines~~very ~~from~~quickly, ~~all~~which ~~sources~~in ~~including botanical~~turn, ~~traditional~~reduces ~~chemical~~the ~~synthesis~~cost ~~and biosynthetic~~of ~~methodologies~~production.

OnNano4M ~~May~~Ltd ~~28,~~is ~~2021, we acquired ABTI Pharma Limited,~~ a company ~~registered~~which inhas ~~England~~exclusively ~~and Wales (“ABTI Pharma”), with the purchase of all of~~ licensed its ~~capital~~nano-formulation ~~stock~~patents inand ~~exchange~~know-how ~~for 600,000,000 shares of our common stock pro rata~~ to ~~the~~ ABTI Pharma ~~shareholders~~Ltd.

AsAdditionally, awe ~~result~~may ofconsider ~~the~~entering ~~acquisition~~into Joint Venture Partnerships, weor ~~are~~acquire acompanies ~~pharmaceutical~~with complimentary portfolios or enter into Licensing Agreements to enhance the product portfolio. ~~company~~These ~~working~~are ~~with~~strategies ~~cannabinoid~~the Company may implement and ~~cannabinoid~~any ~~like~~such ~~molecules.~~opportunities Wewill ~~have~~be ~~three~~assessed ~~areas~~on ofa ~~focus:~~case by case basis and on their merit at the time.

1)Alterola ~~Development~~and ofABTI ~~regulated~~Pharma ~~pharmaceuticals~~Ltd ~~(human~~management have extensive experience, know-how and ~~animal~~connections ~~health)~~in the cannabinoid medicines sector, and ~~regulated~~are ~~food~~looking ~~products.~~to ~~This~~utilize ~~has~~this ~~been~~knowledge ~~achieved~~and ~~via~~experience for the ~~strategic~~development ~~acquisition~~ of ~~Phytotherapeutix~~such ~~Ltd~~medicines from existing cannabinoids and cannabinoid-like molecules.;

2)Our ~~Production~~address ofis ~~low~~47 ~~cost~~Hamilton ofSquare ~~goods~~Birkenhead ~~Active~~Merseyside CH41 ~~Pharmaceutical~~5AR ~~Ingredient~~United ~~(API)~~Kingdom. Our telephone number is +44 151 601 9477. Our website is www.alterolabio.com. The company has a fully operational US$ and ~~food-grade~~a ~~ingredients~~£ ~~(supported~~sterling bybank account in the ~~strategic~~United ~~acquisition~~Kingdom ofwith ~~Ferven~~the ~~Ltd);~~HSBC ~~and~~Group.

3)We ~~Formulation~~do not incorporate the information on or accessible through our websites into this Quarterly Report, and ~~drug~~you ~~delivery,~~should ~~providing~~not ~~improved~~consider ~~bioavailability,~~any ~~solubility~~information ~~and~~on, ~~stability~~or ~~(supported~~that bycan ~~the~~be ~~exclusive~~accessed ~~licensing~~through, ofour websites IPa ~~and~~part ~~technology~~of ~~from~~this ~~Nano4M~~Quarterly ~~Ltd)~~Report.

~~Phytotherapeutix~~Results ~~Ltd, a subsidiary~~ of ~~ABTI~~Operations ~~Pharma Ltd,~~for ~~has~~the ~~generated~~Three aand ~~number~~Nine ofMonths Ended ~~molecules~~December ~~with patents pending~~31, ~~some~~2023 ofand which have demonstrable pharmacological activity, similar to that of CBD. This means that some of these molecules are anticipated to have a similar market potential to CBD across a range of therapeutic areas.2022

~~Ferven~~We have ~~Ltd,~~generated ~~another~~no ~~subsidiary~~revenues ofsince ~~ABTI~~inception ~~Pharma~~and ~~Ltd, is~~we ~~looking~~do tonot ~~produce~~anticipate ~~cannabinoids~~earning byrevenue ~~fermentation.~~until ~~The~~such ~~exclusively~~time ~~licensed~~that ~~organism~~we ~~has~~are ~~the~~able ~~potential~~ to bemarket ~~genetically~~and ~~modified to~~sell ~~produce~~our ~~multiple~~ingredients ~~cannabinoids~~and at/ anor ~~anticipated~~products ~~very~~/ ~~low cost of goods~~medicines. ~~It is anticipated that the selected genetically modified organisms will grow very quickly, which in turn, reduces the cost of production.~~

~~Nano4M~~We ~~Ltd~~incurred isoperating aexpenses ~~company~~of ~~which~~$1,108,947 ~~has~~for ~~exclusively~~the three ~~licensed~~months ended December 31, 2023, as compared with $540,621 for the same period ended 2022. We incurred operating expenses of $1,825,671 ~~its~~for ~~nano-formulation~~the ~~patents~~nine ~~and~~months ~~know-how~~ended toDecember ~~ABTI~~31, ~~Pharma~~2023, ~~Ltd~~as compared with $1,823,992 for the same period ended 2022.

~~Additionally~~Our operating expenses for the nine months ended December 31, we2023 ~~may~~increased ~~consider~~over ~~entering~~the ~~into~~same ~~Joint~~period in 2022 mainly as a result of more spent on consulting fees and accounting and audit fees. Our ~~Venture~~operating ~~Partnerships~~expenses for the nine months ended December 31, or2023 ~~acquire~~were ~~companies~~mainly ~~with~~the ~~complimentary~~result ~~portfolios~~of or$995,099 ~~enter~~in ~~into~~consulting ~~Licensing~~fees, ~~Agreements~~$273,659 toin ~~enhance~~professional fees, ~~the~~$227,575 ~~product~~in ~~portfolio~~director fees and expenses, $99,982 in accounting and audit fees, and $96,315 in salaries and wages. Our operating expenses ~~These~~for ~~are~~the ~~strategies~~nine months ended December 31, 2022 were mainly the ~~Company~~result ~~may~~of ~~implement~~$546,571 in directors fees and ~~any~~expenses, ~~such~~$481,429 ~~opportunities~~in ~~will~~consulting fees, be$363,193 ~~assessed~~in onprofessional afees, ~~case~~$101,238 byin ~~case~~salaries ~~basis~~and wages, $86,816 in accounting and onaudit ~~their~~fees ~~merit at~~and ~~the~~$41,086 ~~time~~in research and development.

~~Alterola~~We ~~and~~had ~~ABTI~~other ~~Pharma~~expenses ~~Ltd~~of ~~management~~$406,575 ~~have~~and ~~extensive experience~~$544,738 ~~know-how~~for the three and ~~connections~~nine inmonths ~~the~~ended ~~cannabinoid~~December ~~medicines~~31, ~~sector~~2023, ~~and~~respectively, ~~are~~for ~~looking~~losses toon ~~utilize~~the ~~this~~conversion ~~knowledge~~of ~~and~~a ~~experience~~note, ~~for the~~with ~~development~~no ofother ~~such~~expense ~~medicines~~for ~~from~~the same ~~existing~~periods ~~cannabinoids~~ended ~~and~~December ~~cannabinoid-like~~31, ~~molecules~~2022.

~~Our~~If ~~address~~we isare 47able ~~Hamilton~~to ~~Square~~obtain ~~Birkenhead~~financing, ~~Merseyside~~we expect that ~~CH41~~our ~~5AR~~operational ~~United~~expenses ~~Kingdom.~~will ~~Our~~increase ~~telephone~~significantly ~~number~~for isthe ~~+44~~balance ~~151~~of ~~601~~the ~~9477.~~fiscal ~~Our~~year ~~website~~ended isMarch ~~www.alterolabio.com.~~31, ~~The~~2024 ~~company~~and ~~has~~beyond. aThis ~~fully~~would ~~operational~~be ~~US$~~the result of increased research and adevelopment £expenses ~~sterling~~associated ~~bank~~with ~~account~~our product candidates, the development of those candidates in compliance with regulatory processes, laws and regulations, increased payroll as we take on more help, as well as the ~~United~~expenses ~~Kingdom~~associated with our reporting obligations with the ~~HSBC~~Securities ~~Group~~and Exchange Commission.

We dorecorded ~~not~~a ~~incorporate~~net ~~the~~loss ~~information~~of on$1,515,522 orfor ~~accessible~~the three ~~through~~months ~~our~~ended ~~websites~~December ~~into~~31, ~~this~~2023, ~~Quarterly~~as ~~Report~~compared with $534,789 ~~and~~for ~~you~~the ~~should~~same ~~not~~period ~~consider~~ended ~~any~~2022. ~~information~~We onrecorded a net loss of $2,370,409 orfor ~~that~~the nine ~~can~~months beended ~~accessed~~December ~~through~~31, ~~our websites~~2023, aas ~~part~~compared ofwith ~~this~~$1,722,691 ~~Quarterly~~for ~~Report~~the same period ended 2022.

Table of Contents

~~Results~~As ofa ~~Operations~~relatively recently formed pharmaceutical company, the company has limited operations to date, and expects to have reoccurring losses, as is typical with companies in the pharmaceutical industry, for the ~~Three~~foreseeable future. As explained above, the company intends to raise capital and ~~Six~~ramp ~~Months~~up its efforts to bring its product ~~Ended~~candidates ~~September~~to 30market. This will require significant capital, ~~2023~~product development to continue and ~~2022~~complete and momentum on those product candidates through the regulatory process. There are no assurances that we will be able to generate revenues and achieve profitable operations.

~~We have~~Liquidity ~~generated no revenues since inception~~ and weCapital ~~do not anticipate earning revenue until such time that we are able to market and sell our ingredients and / or products / medicines.~~ Resources

WeAs ~~incurred~~of ~~operating~~December ~~expenses~~31, of2023, we had $~~123~~198,~~155~~389 ~~for~~in ~~the~~current ~~three~~assets, ~~months~~consisting ~~ended~~mostly ~~September~~of ~~30,~~a ~~2023,~~deferred astax ~~compared with $470~~credit,~~682~~ ~~for~~and ~~the~~current ~~same~~liabilities ~~period~~of ~~ended 2022~~$1,358,424. We ~~incurred~~had ~~operating~~a ~~expenses~~working capital deficit of $~~716~~1,~~724~~160,035 ~~for~~as ~~the~~of ~~six~~December ~~months ended September 30~~31, 2023, as compared with a working capital deficit of $12,~~283~~322,~~371~~023 ~~for~~as ~~the~~of ~~same~~September ~~period~~30, ~~ended 2022~~2023.

~~Our~~We used cash for operating ~~expenses~~activities of $1,513,275 for the ~~six~~nine months ended ~~September 30~~December 31, 2023, ~~decreased~~as ~~over~~compared with cash used of $1,156,498 for the same period inended 2022. ~~mainly~~Our asnegative aoperating cash ~~result~~flow ofthe ~~less~~nine ~~spent~~months onended ~~director~~December ~~fees~~31, ~~and~~2023 ~~professional~~was ~~fees.~~mainly ~~Our~~the ~~director fees~~result ~~and~~of ~~expenses~~a ~~were~~net ~~$196~~loss,~~000~~ ~~and~~offset ~~our~~mainly ~~professional~~by ~~fees~~shares ~~were~~issued $7for services,~~185~~ ~~for~~to directors ~~the~~and ~~six~~others. ~~months~~Our ~~ended~~negative ~~September~~operating ~~30,~~cash ~~2023,~~flow asfor ~~compared~~2022 ~~with~~was ~~$518,640 in~~mainly ~~director~~the ~~fees~~result ~~and~~of ~~$114~~a net loss,~~010~~ net changes in ~~professional~~operating ~~fees~~assets ~~for~~and liabilities ~~the~~and ~~six~~deferred ~~months~~tax ~~ended~~credit ~~September~~offset ~~30,~~by ~~2022~~shares issued for services.

We used ~~also~~$0 ~~had~~in nocash ~~expenses~~ for ~~research~~investing ~~and~~activities ~~development~~ for the ~~six~~nine months ended ~~September~~December 3031, 2023, as compared with $4118,~~086~~147 in ~~research~~cash ~~and development~~ provided for the ~~six~~same ~~months~~period ended ~~September 30,~~ 2022.

IfFinancing weactivities ~~are~~provided ~~able to obtain financing~~$1,289,563 ~~we expect that our operational expenses will increase significantly~~ for the ~~balance~~nine months ~~of the fiscal year~~ ended ~~March~~December 31, ~~2024~~2023, ~~and~~mainly ~~beyond.~~as ~~This~~a ~~would be the~~ result of ~~increased~~shares ~~research~~issued ~~and~~for ~~development~~conversion ~~expenses~~of ~~associated~~debt ~~with~~to ~~our~~equity ~~product~~and ~~candidates,~~loan ~~the~~from ~~development~~related ofparties. ~~those candidates~~Financing inactivities ~~compliance~~provided ~~with regulatory processes~~$1, ~~laws and regulations~~093,405 ~~increased~~for ~~payroll~~the asnine wemonths ~~take~~ended onDecember ~~more~~31, ~~help~~2022, as ~~well~~a asresult ~~the~~of ~~expenses~~related ~~associated with~~party ~~our reporting obligations with the Securities and Exchange Commission~~notes.

WeBased upon ~~recorded~~our acurrent ~~net~~financial ~~loss~~condition, ofwe ~~$123,155~~do not have sufficient cash to operate our business at the current level for the ~~three~~ next 12 months. We ~~ended~~intend ~~September~~to ~~30,~~fund ~~2023,~~operations asthrough ~~compared~~short-term ~~with~~or ~~$375~~long-term debt and/or equity financing arrangements,~~252~~ ~~for~~however ~~the~~this ~~same~~may ~~period~~be ~~ended~~insufficient to ~~2022~~fund expenditures or other cash requirements. We ~~recorded~~plan to seek additional financing in a ~~net~~private ~~loss~~equity ofoffering ~~$854,887~~to ~~for~~secure ~~the~~funding for ~~six~~operations. ~~months~~There ~~ended~~can ~~September~~be ~~30,~~no ~~2023,~~assurance asthat ~~compared~~we ~~with~~will ~~$1,187,941~~be ~~for~~successful in raising additional funding. If we are not able to secure additional funding, the ~~same~~implementation ~~period~~of ~~ended~~our ~~2022~~business plan will be impaired. There can be no assurance that such additional financing will be available to us on acceptable terms or at all.

AsOff aBalance ~~relatively~~Sheet recently formed pharmaceutical company, the company has limited operations to date, and expects to have reoccurring losses, as is typical with companies in the pharmaceutical industry, for the foreseeable future. As explained above, the company intends to raise capital and ramp up its efforts to bring its product candidates to market. This will require significant capital, product development to continue and complete and momentum on those product candidates through the regulatory process. There are no assurances that we will be able to generate revenues and achieve profitable operations.Arrangements

~~Liquidity~~As ~~and~~of ~~Capital~~December ~~Resources~~31, 2023, we had no off-balance sheet arrangements.

AsGoing of September 30, 2023, we had $197,208 in current assets, consisting mostly of a deferred tax credit, and current liabilities of $2,519,231. We had a working capital deficit of $2,322,023 as of September 30, 2023, compared with a working capital deficit of $1,889,920 as of March 31, 2023.Concern

WeOur financial ~~used~~statements ~~cash~~were ~~for~~prepared ~~operating~~assuming ~~activities~~we will continue as a going concern which contemplates the realization of ~~$197,625~~assets and satisfaction ~~for~~of liabilities in the ~~six~~normal ~~months~~course ~~ended~~of ~~September~~business. ~~30,~~We ~~2023~~have negative working capital of $1,160,035 as of ~~compared~~December ~~with~~31, ~~cash~~2023, ~~used~~and have an accumulated deficit of $~~363~~11,~~213~~946,656. ~~for~~We expect to incur further losses in the ~~same~~development ~~period~~of ~~ended~~our ~~2022~~business and have been dependent on funding operations from inception. ~~Our~~These ~~negative~~conditions ~~operating~~raise substantial doubt about our ability to continue as a going concern. Management’s plans include ~~cash~~continuing ~~flow~~to finance operations through the ~~six~~private ~~months~~or ~~ended~~public ~~September~~placement ~~30,~~of ~~2023~~debt ~~was~~and/or ~~mainly~~equity securities and the ~~result~~reduction of aexpenditures. However, ~~net~~no ~~loss,~~assurance ~~offset~~can bybe ~~shares~~given ~~issued~~at ~~for~~this ~~services,~~time as to ~~directors and~~whether ~~others~~we will be able to achieve these objectives. ~~Our~~The ~~negative~~financial ~~operating~~statements ~~cash~~do not ~~flow~~include any adjustment relating to the ~~six~~recoverability ~~months~~and ~~ended~~classification ~~September~~of ~~30,~~recorded ~~2022~~asset ~~was~~amounts ~~mainly~~or the ~~result~~amounts and classification of aliabilities ~~net~~that ~~loss,~~might ~~offset~~be bynecessary ~~shares issued~~should ~~for~~we ~~services~~be ~~and~~unable ~~stock~~to ~~subscriptions~~continue ~~delivered~~as a going concern.

We used $35,000 in cash for investing activities for the six months ended September 30, 2023, as compared with no cash used for the same period ended 2022., as a result of intellectual property acquired from Alinova Biosciences Ltd.

Financing activities provided $75,530 for the six months ended September 30, 2023, as a result of related party notes.

Financing activities provided $296,947 for the six months ended September 30, 2022, as a result of related party notes.

As part of the SPA, executed on October 03, 2022, the shareholder affiliates, through their respective companies, have committed to enter into loan agreements with our company to provide up to $4,000,000 USD of working capital. To date, these shareholder affiliates have only received a total of $2,350,000 USD. In accordance with the terms of the loan agreements, the shareholder affiliates had the right to call in the loans from the maturity date (June 03, 2023).

Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next 12 months. We intend to fund operations through short-term or long-term debt and/or equity financing arrangements, however this may be insufficient to fund expenditures or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding, the implementation of our business plan will be impaired. There can be no assurance that such additional financing will be available to us on acceptable terms or at all.

Table of Contents

Off Balance Sheet Arrangements

As of September 30, 2023, we had no off-balance sheet arrangements.

Going Concern

Our financial statements were prepared assuming we will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We have negative working capital of $2,322,023 as of September 30, 2023, and have an accumulated deficit of $10,431,134. We expect to incur further losses in the development of our business and have been dependent on funding operations from inception. These conditions raise substantial doubt about our ability to continue as a going concern. Management’s plans include continuing to finance operations through the private or public placement of debt and/or equity securities and the reduction of expenditures. However, no assurance can be given at this time as to whether we will be able to achieve these objectives. The financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

A smaller reporting company is not required to provide the information required by this Item.

Table of Contents

Item 4. Controls and Procedures

Disclosure Controls and Procedures

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of ~~September~~December 3031, 2023. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of ~~September~~December 3031, 2023, our disclosure controls and procedures were not effective due to the presence of material weaknesses in internal control over financial reporting.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of ~~September~~December 3031, 2023, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

Remediation Plan to Address the Material Weaknesses in Internal Control over Financial Reporting

Our company plans to take steps to enhance and improve the design of internal controls over financial reporting. OnIn October 2023, the company appointed a new Chief Financial Officer. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we plan to implement the following changes during our fiscal year ending March 31, 2024: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

Changes in Internal Control over Financial Reporting

Aside from above, there were no changes in our internal control over financial reporting during the three months ended ~~September~~December 3031, 2023 that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

We are not a party to any pending legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

Item 1A: Risk Factors

Please see the Risk Factors contained in our Annual Report on Form 10-K filed with the SEC on July 10, 2023, which are incorporated herein by reference.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On September 8, 2023, the Company entered into an Agreement to ~~Return~~sell ~~Assets~~assets ~~and~~to ~~Shares~~ with C2 Wellness Corp. As part of the agreement, the company received 29,015,996 shares of ABTI stock and sold ~~returned~~ all assets related to the acquisition, resulting in a write-off of $12,000,000 in intangibles.

On October 16, 2023, TPR Global Limited, Equipped 4 Holdings Limited and Phytotherapeutix Holdings Ltd converted a total of $2.35m USD of debt in the Company into common shares at a price of $0.004 per share.

The issuance of the shares is exempt from registration in reliance upon Section 4(2) and/or Regulation D of the Securities Act of 1933, as amended.

Item 3. Defaults upon Senior Securities

None

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

On October 10, 2023, Mr. Tim Rogers resigned as Chief Financial Officer and Mr. David Hitchcock resigned as company Secretary. On the same day, Mr. Nathan Thompson was appointed as Chief Financial Officer and Secretary. At present, we do not have a compensation arrangement with Mr. Thompson.

~~Item~~On 6October 13, 2023, we revised the Audit Committee membership, with Mr. Hunter ~~Exhibits~~Land appointed to serve on the audit committee of the company. The committee is now comprised of Ning Qu as Chairperson and Mr. Land, both independent directors of ther company.

Exhibit Number	Description of Exhibit
31.1**	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2**	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101**	The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 formatted in Extensible Business Reporting Language (XBRL).
**Provided herewith

On October 16, 2023, Terry Raif was removed from the Board of Directors by shareholder vote.

8On October 20, 2023, the company dismissed Gries and Associtaes as the company’s independent auditor and appointed GreenGrowth CPAs as the company’s independent auditor.

~~Table of Contents~~Item 6. Exhibits

SIGNATURES

Exhibit Number	Description of Exhibit
31.1**	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2**	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101**	The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2023 formatted in Extensible Business Reporting Language (XBRL).
**Provided herewith

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.~~8

	Alterola Biotech, Inc.
Date:	November 21, 2023
	By: /s/ David Hitchcock David Hitchcock Title: Chief Executive Officer (Principal Executive Officer) and Director

Table of Contents

~~Date: November 21, 2023 By: /s/ Nathan Thompson Nathan Thompson Title: Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer), and Director~~SIGNATURES

9Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Alterola Biotech, Inc.

Date:	February 20, 2024

	By: /s/ David Hitchcock David Hitchcock Title: Chief Executive Officer (Principal Executive Officer) and Director

Date:

February 20, 2024

By: /s/ Nathan Thompson

Nathan Thompson

Title: Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer), and Director

Filing Compare · ALTEROLA BIOTECH INC.